Frontiers in Medicine (Sep 2022)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis

  • Cristiano Caruso,
  • Paolo Cameli,
  • Elena Altieri,
  • Maria Aliani,
  • Pietro Bracciale,
  • Luisa Brussino,
  • Maria Filomena Caiaffa,
  • Giorgio Walter Canonica,
  • Giorgio Walter Canonica,
  • Stefano Centanni,
  • Maria D’Amato,
  • Stefano Del Giacco,
  • Fausto De Michele,
  • Elide Anna Pastorello,
  • Girolamo Pelaia,
  • Paola Rogliani,
  • Paola Rogliani,
  • Micaela Romagnoli,
  • Pietro Schino,
  • Marco Caminati,
  • Marco Caminati,
  • Alessandra Vultaggio,
  • Alessandro Zullo,
  • Sara Rizzoli,
  • Silvia Boarino,
  • Gianfranco Vitiello,
  • Francesco Menzella,
  • Fabiano Di Marco

DOI
https://doi.org/10.3389/fmed.2022.950883
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundSevere asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of debate. Indeed, switching between biologics is common, but no official guidelines are available and real-world data are limited.Materials and methodsIn this post hoc analysis of the Italian, multi-center, observational, retrospective study, ANANKE. Patients with severe eosinophilic asthma treated with benralizumab were divided in two groups based on history of previous biologic therapy (biologic-experienced [suboptimal response] vs naïve). Baseline clinical and laboratory characteristics were collected in the 12 months prior to benralizumab treatment. Change over time in blood eosinophils, annualized exacerbation rate (AER), asthma control (ACT), lung function and oral corticosteroid (OCS) use following benralizumab initiation were collected in the two groups.ResultsA total of 147 biologic-naïve and 58 biologic-experienced (34 omalizumab, 19 mepolizumab, and 5 omalizumab-mepolizumab) patients were enrolled. Biologic-experienced patients were more likely to be atopic and have a higher AER despite more frequent OCS use. Similar reductions in AER (>90% in both groups), OCS use (≥49% reduction in dosage and ≥41% able to eliminate OCS), ACT improvement (≥7 points gained in 48 weeks) and lung function (≥300 mL of FEV1 improvement in 48 weeks) were observed after benralizumab introduction within the two groups. There were no registered discontinuations of benralizumab for safety reasons.ConclusionIn this post hoc analysis, patients who were switched to benralizumab because of suboptimal control with a previous biologic therapy were more likely to be atopic and more often treated with omalizumab. Benralizumab is effective in both naïve patients and those previously treated with a biologic.

Keywords